All In Biotech

Drug Trial Radar · NCT00634166

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group

Last checked: Nov 19, 2026Latest source record: Sep 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

220

Actual

Start

Sep 2007

Primary completion

Dec 2013

Study completion Apr 2014

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
Mylan Bertek Pharmaceuticals
First posted
Mar 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to compare the effectiveness of treatment with Sulfamylon® solution as the initial topical moist dressing over meshed autografts following the initial graft procedure on preventing graft loss in a prospective cohort of subjects versus a historical control group in a non-inferiority trial.

Conditions

  • Burns

Interventions

  • Sulfamylon® For 5 % Topical SolutionDrug

    Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.

  • Topical Antimicrobial/Antifungal MedicationsDrug

    'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Graft Loss After Initial Meshed Autograft Procedure on Days 5-7.Time frame: The primary analysis will compare the percent of subjects with All Cause Graft Loss of the initial meshed autograft procedure at Days 5-7.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama Medical Center

    Mobile, Alabama

  • Arrowhead Regional Medical Center

    Redlands, California

  • Shands Burn Center - Univ. of Florida

    Gainesville, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • The Plastic Surgery Institute - Southern Illinois Univ. School of Medicine

    Springfield, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • John's Hopkins Burn Center

    Baltimore, Maryland

  • University of Missouri Healthcare - Dept. of Surgery

    Columbia, Missouri

  • Wake Forest University - Department of General Surgery

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.